Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Favorable-Risk mRCC: Treatment Approaches

August 3rd 2021

A panel discussion regarding individual preferences for treating favorable-risk metastatic renal cell carcinoma.

Favorable-Risk mRCC: When to Initiate Therapy

August 3rd 2021

Dr Amishi Y. Shah, of MD Anderson Cancer Center, describes the rationale for active surveillance vs treatment with a novel therapeutic in metastatic renal cell carcinoma.

Dr. Dreicer on the Clinical Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer

July 28th 2021

Robert Dreicer, MD, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in locally advanced or metastatic urothelial cancer.

Pal Provides Perspective on Pivotal Trials in RCC and Prostate Cancer

July 27th 2021

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

Intermediate/Poor-Risk mRCC: Treatment Selection

July 27th 2021

Factors oncologists should consider prior to selecting a novel treatment approach for metastatic renal cell carcinoma.

Intermediate/Poor-Risk mRCC: I-O/I-O Vs I-O/TKI Therapy

July 27th 2021

Variables that impact one’s decision to treat metastatic renal cell carcinoma with an immunotherapy-based regimen that includes a targeted agent vs additional immunotherapy.

FDA Issues a Complete Response Letter for Retifanlimab for Squamous Cell Carcinoma of the Anal Canal

July 26th 2021

The FDA has issued a complete response letter to Incyte Corporation stating that it cannot approve the biologics license application for retifanlimab for use in adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who have progressed on, or who are intolerant of, platinum-based chemotherapy, in its present form.

Brain Metastases Occur in Significant Percentage of Advanced RCC, Underscoring Potential Role for Routine Brain Imaging

July 23rd 2021

Brain imaging should be considered for patients with advanced or metastatic renal cell carcinoma who have a high metastatic burden and who have progressed after treatment with first-line therapies.

FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer

July 22nd 2021

Dr. Tagawa discusses the FDA approval of sacituzumab govitecan in urothelial cancer, key efficacy and safety data from the pivotal TROPHY-U-01 trial, and expectations for the confirmatory TROPiCS-04 trial.

Dr. Motzer on the Importance of Assessing Health-Related QOL in RCC

July 20th 2021

Robert J. Motzer, MD, discusses the importance of assessing health-related quality of life in renal cell carcinoma.

I-O/TKI Regimens for Metastatic RCC: Dosing Strategies

July 20th 2021

Recommendations for dosing targeted therapy-immunotherapy combinations used to treat patients with metastatic renal cell carcinoma.

The CLEAR Trial in Metastatic RCC

July 20th 2021

Characteristics that distinguish the CLEAR trial of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma from other pivotal trials of immunotherapy plus tyrosine kinase inhibitors.

BLA for Vicineum in High-Risk, BCG-Unresponsive NMIBC Remains on Track for Regulatory Decision

July 16th 2021

A Late-Cycle Meeting was held to discuss the biologics license application for Vicineum as a potential option for patients with Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer.

Frontline Metastatic RCC: Nivolumab Plus Cabozantinib

July 13th 2021

Robert S. Alter, MD, provides key takeaways from the CheckMate 9ER study of nivolumab plus cabozantinib as frontline therapy for patients with metastatic renal cell carcinoma.

Frontline Metastatic RCC: Pembrolizumab Plus Axitinib

July 13th 2021

Thomas Powles, MD, MBBS, MRCP, describes the KEYNOTE-426 trial in frontline metastatic renal cell carcinoma and comments on the use of pembrolizumab plus axitinib for appropriate patients.

Darolutamide Demonstrates Favorable Tolerability in Nonmetastatic CRPC

July 12th 2021

Treatment with darolutamide induced a low cumulative incidence of hormone treatment–related adverse effects that was comparable to treatment with placebo in patients with nonmetastatic castration-resistant prostate cancer, according to findings from a safety analysis of the phase 3 ARAMIS trial.

FDA Grants Regular Approval to Enfortumab Vedotin, Expands Indication for Locally Advanced or Metastatic Urothelial Cancer

July 9th 2021

The FDA has granted a regular approval to enfortumab vedotin-ejfv and has expanded the agent's indication to include adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and who have received 1 or more prior lines of therapy.

Urologic Care Rates Decline Across US Demographics During Height of COVID-19 Pandemic

July 9th 2021

The provision of urologic care underwent a significant decline during the height of the COVID-19 pandemic across all demographic groups and practice settings in the United States, regardless of the timing of stay-at-home order mandates.

Lenvatinib/Pembrolizumab’s Favorable HRQoL Leads to “Standout” Option for Frontline RCC

July 9th 2021

Robert J. Motzer, MD, discusses the efficacy and health-related quality of life benefits of lenvatinib/pembrolizumab in patients with advanced RCC, and projected where the regimen might fit into the treatment paradigm.

Frontline Metastatic RCC: Nivolumab Plus Ipilimumab

July 6th 2021

Amishi Y. Shah, MD, comments on the significance of updated survival data revealed by the CheckMate 214 study using the combination of ipilimumab plus nivolumab as frontline therapy for metastatic renal cell carcinoma.